TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...
(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...
Inhibitor Drugs to Treat Aggressive Breast ... 2025 — Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing ...
I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer.
Explore the role of the extracellular matrix (ECM) in prostate cancer progression and discover natural therapies, including ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback